Physician profile
Bethany Pennington
NPI 1598310450
$1,228.05
in general payments reported to CMS, 2019-2025
15 companies · $658 in 2025
The $658 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $45.89 · 2023: $289 · 2024: $235 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,182.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $503.53 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $162.37 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $133.33 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $105.57 | 2023-2024 | Mounjaro |
| Amgen INC. | $60.21 | 2025 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $55.73 | 2024-2025 | Airsupra |
| Exact Sciences Corporation | $47.63 | 2023-2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $29.54 | 2023-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $26.36 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $24.40 | 2023 | Rexulti |
| Vertex Pharmaceuticals Incorporated | $20.17 | 2025 | |
| Paratek Pharmaceuticals, INC. | $15.88 | 2024 | Nuzyra |
| Cipher Pharmaceuticals US LLC | $15.52 | 2025 | Natroba, Spinosad |
| Pfizer INC. | $14.56 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.25 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Pennington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.